PLK1 and glioblastoma: Inhibition of PLK1 kinase activity by PLK1 inhibitors such as volasertib, BI 2536, and GSK461364 has been shown to induce cell cycle arrest at the G2/M phase in glioblastoma cells, osteosarcoma and NSCLC cells [30, 31, 36–38].